This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
Estrogen Receptor alpha Monoclonal Antibody (6F11)
catalog :
MA5-13304
quantity :
500 µL
price :
US 496
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
6F11
reactivity :
African green monkey, human, rat, chicken, pigs , cat, domestic rabbit
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, EMSA, immunohistochemistry - paraffin section, immunohistochemistry - frozen section
citations: 68
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; cat; 1:125; loading ...; tbl 4
Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, et al. Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. Oncotarget. 2016;7:17314-26 pubmed publisher
  • immunohistochemistry; cat; 1:100; loading ...; fig 1a
Soares M, Correia J, Peleteiro M, Ferreira F. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol. 2016;37:4053-64 pubmed publisher
  • immunohistochemistry; pigs ; fig s5
Rowson Hodel A, Manjarin R, Trott J, Cardiff R, Borowsky A, Hovey R. Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo. BMC Cancer. 2015;15:562 pubmed publisher
  • immunocytochemistry; rat
Tkalia I, Vorobyova L, Grabovoy A, Svintsitsky V, Tarasova T. The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats. Exp Oncol. 2015;37:30-5 pubmed
  • immunohistochemistry; human
  • immunohistochemistry; rat
Tkalia I, Vorobyova L, Grabovoy A, Svintsitsky V, Tarasova T, Lukyanova N, et al. Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor. Exp Oncol. 2014;36:184-90 pubmed
  • immunohistochemistry; human; 1:200
Khandakar B, Mathur S, Kumar L, Kumar S, Datta Gupta S, Iyer V, et al. Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int. 2014;2014:401245 pubmed publisher
  • western blot; human
Lee J, Tiwari A, Shum V, Mills G, Mancini M, Igoshin O, et al. Unraveling the regulatory connections between two controllers of breast cancer cell fate. Nucleic Acids Res. 2014;42:6839-49 pubmed publisher
  • immunohistochemistry; human; 1:100
Bredow L, Stützel L, Böhringer D, Gundlach E, Reinhard T, Auw Haedrich C. Progesterone and estrogen receptors in conjunctival melanoma and nevi. Graefes Arch Clin Exp Ophthalmol. 2014;252:359-65 pubmed publisher
  • EMSA; human
Kruer T, Cummins T, Powell D, Wittliff J. Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior. Clin Biochem. 2013;46:1739-46 pubmed publisher
  • immunohistochemistry; human; 1:50
Grosso S, Katayama M, Roela R, Nonogaki S, Soares F, Brentani H, et al. Breast cancer tissue slices as a model for evaluation of response to rapamycin. Cell Tissue Res. 2013;352:671-84 pubmed publisher
  • western blot; human
Endoh T, Kawasaki Y, Sugimoto N. Stability of RNA quadruplex in open reading frame determines proteolysis of human estrogen receptor ?. Nucleic Acids Res. 2013;41:6222-31 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
Corrêa N, Kuasne H, Faria J, Seixas C, Santos I, Abreu F, et al. Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors. Oncol Rep. 2013;29:1299-307 pubmed publisher
  • immunohistochemistry; human
  • western blot; human
Li Y, Meeran S, Patel S, Chen H, Hardy T, Tollefsbol T. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Mol Cancer. 2013;12:9 pubmed publisher
  • immunocytochemistry; human; 1:35
Marinšek Z, Nolde N, Kardum Skelin I, Nizzoli R, Onal B, Rezanko T, et al. Multinational study of oestrogen and progesterone receptor immunocytochemistry on breast carcinoma fine needle aspirates. Cytopathology. 2013;24:7-20 pubmed publisher
  • immunohistochemistry; human; 1:100
Marian C, Boilă A, Soanca D, Malau M, Podeanu D, Resetkova E, et al. Malignant transformation of adenomyoepithelioma of the breast by a monophasic population: a report of two cases and review of literature. APMIS. 2013;121:272-9 pubmed publisher
  • immunohistochemistry; human
Gill M, Paish E, Ronan J, Green A, Ellis I, Lee A. Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast. Appl Immunohistochem Mol Morphol. 2013;21:90-3 pubmed publisher
  • immunohistochemistry; chicken; 1:200
Machado S, Bahr J, Hales D, Braundmeier A, Quade B, Nowak R. Validation of the aging hen (Gallus gallus domesticus) as an animal model for uterine leiomyomas. Biol Reprod. 2012;87:86 pubmed publisher
  • immunohistochemistry; human; 1:50
Martins F, De S, Almendro V, Gonen M, Park S, Blum J, et al. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012;2:503-11 pubmed publisher
  • immunohistochemistry; human; 1:100
Hovanessian Larsen L, Taylor D, Hawes D, Spicer D, Press M, Wu A, et al. Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception. 2012;86:238-43 pubmed publisher
  • immunohistochemistry; human
Maae E, Olsen D, Steffensen K, Jakobsen E, Brandslund I, Sørensen F, et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat. 2012;133:257-65 pubmed publisher
  • immunohistochemistry; human; 1:100
Chung K, Hovanessian Larsen L, Hawes D, Taylor D, Downey S, Spicer D, et al. Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation. Breast Cancer Res Treat. 2012;132:653-60 pubmed publisher
  • immunohistochemistry; human; 1:50
Logullo A, Stiepcich M, Osório C, Nonogaki S, Pasini F, Rocha R, et al. Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology. 2011;58:617-25 pubmed publisher
  • immunohistochemistry; human; 1:50
Joosse S, Brandwijk K, Mulder L, Wesseling J, Hannemann J, Nederlof P. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer. 2011;50:71-81 pubmed publisher
  • immunohistochemistry; human; 1:50
Holstege H, van Beers E, Velds A, Liu X, Joosse S, Klarenbeek S, et al. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer. 2010;10:455 pubmed publisher
  • immunohistochemistry; human; 1:50
Joosse S, Brandwijk K, Devilee P, Wesseling J, Hogervorst F, Verhoef S, et al. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Res Treat. 2012;132:379-89 pubmed publisher
  • immunohistochemistry; human; 1:50
Roepman P, Horlings H, Krijgsman O, Kok M, Bueno de Mesquita J, Bender R, et al. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res. 2009;15:7003-11 pubmed publisher
  • immunohistochemistry; human; 1:200
Bueno de Mesquita J, Nuyten D, Wesseling J, VAN Tinteren H, Linn S, van de Vijver M. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol. 2010;21:40-7 pubmed publisher
  • immunohistochemistry; cat
Misirlioglu D, Nak D, Ozyigit M, Nak Y, Akkoc A. HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats. J Feline Med Surg. 2009;11:885-8 pubmed publisher
  • immunohistochemistry; human; 1:50
Pietersen A, Horlings H, Hauptmann M, Langerød A, Ajouaou A, Cornelissen Steijger P, et al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 2008;10:R109 pubmed publisher
  • immunohistochemistry; human; 1:100
Chakravarty D, Srinivasan R, Ghosh S, Rajwanshi A, Gopalan S. Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. Appl Immunohistochem Mol Morphol. 2008;16:535-42 pubmed publisher
  • immunohistochemistry; human; 1:50
Horlings H, van Laar R, Kerst J, Helgason H, Wesseling J, van Der Hoeven J, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol. 2008;26:4435-41 pubmed publisher
  • immunohistochemistry; human; 1:50
Joosse S, van Beers E, Tielen I, Horlings H, Peterse J, Hoogerbrugge N, et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat. 2009;116:479-89 pubmed publisher
  • immunohistochemistry - frozen section; human; 1:100
  • immunohistochemistry; human; 1:100
Shi S, Liu C, Pootrakul L, Tang L, Young A, Chen R, et al. Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry. Am J Clin Pathol. 2008;129:358-66 pubmed publisher
  • immunohistochemistry; human
Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13:6064-9 pubmed
  • immunohistochemistry; domestic rabbit; 1:50
Onal B, Levin R, Kogan B, Whitbeck C, Chichester P, Walebowa O, et al. The effect of maturation and age on oestrogen-induced functional hypertrophy of the female rabbit bladder. BJU Int. 2007;99:674-9 pubmed
  • immunohistochemistry; human
Schmidt M, Tollenaar R, de Kemp S, Broeks A, Cornelisse C, Smit V, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25:64-9 pubmed
  • immunohistochemistry; human; 1:50
Hannemann J, Kristel P, VAN Tinteren H, Bontenbal M, van Hoesel Q, Smit W, et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer. 2006;95:1334-41 pubmed
  • immunohistochemistry; human
Wang M, Pan J, Song G, Chen H, An L, Qu S. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol. 2007;33:195-201 pubmed
  • immunohistochemistry; domestic rabbit
Lin A, Levin R, Kogan B, Whitbeck C, Chichester P, Sokol R, et al. Estrogen induced functional hypertrophy and increased force generation of the female rabbit bladder. Neurourol Urodyn. 2006;25:473-9 pubmed
  • western blot; human; 1:100
Turbyville T, Wijeratne E, Liu M, Burns A, Seliga C, Luevano L, et al. Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert. J Nat Prod. 2006;69:178-84 pubmed
  • immunohistochemistry; rat
  • western blot; rat
Weroha S, Li S, Tawfik O, Li J. Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats. Carcinogenesis. 2006;27:491-8 pubmed
  • western blot; human; 1:750
  • immunocytochemistry; African green monkey; 1:200
Lipfert L, Fisher J, Wei N, Scafonas A, Su Q, Yudkovitz J, et al. Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation. Mol Endocrinol. 2006;20:516-33 pubmed
  • immunohistochemistry; human; 1:100
Akhan S, Yavuz E, Tecer A, Iyibozkurt C, Topuz S, Tuzlali S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol. 2005;99:36-42 pubmed
  • immunohistochemistry - paraffin section; human; 1:80; fig 6
Kuo K, Chen M, Lin M. Epithelioid trophoblastic tumor of the broad ligament: a case report and review of the literature. Am J Surg Pathol. 2004;28:405-9 pubmed
  • immunohistochemistry - paraffin section; rat; tbl 1
Goyal H, Braden T, Williams C, Dalvi P, Mansour M, Mansour M, et al. Abnormal morphology of the penis in male rats exposed neonatally to diethylstilbestrol is associated with altered profile of estrogen receptor-alpha protein, but not of androgen receptor protein: a developmental and immunocytochemical study. Biol Reprod. 2004;70:1504-17 pubmed
  • immunohistochemistry - paraffin section; human; tbl 2
Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D. Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: a clinical and immunohistochemical determination. Int J Gynecol Cancer. 2003;13:32-7 pubmed
  • immunohistochemistry - paraffin section; human; tbl 1
Herbert M, Sandbank J, Liokumovich P, Yanai O, Pappo I, Karni T, et al. Breast hamartomas: clinicopathological and immunohistochemical studies of 24 cases. Histopathology. 2002;41:30-4 pubmed
  • immunohistochemistry - paraffin section; human; fig 1
Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int J Gynecol Pathol. 2001;20:341-5 pubmed
Appleyard C, Cruz M, Velazquez Cruz J, Rivera Mendez R, Jimenez Garcia J, Rivera L, et al. Voluntary Wheel Running Reduces Vesicle Development in an Endometriosis Animal Model Through Modulation of Immune Parameters. Front Reprod Health. 2021;3: pubmed publisher
Dustin D, Gu G, Beyer A, Herzog S, Edwards D, Lin H, et al. RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. Br J Cancer. 2021;124:191-206 pubmed publisher
Ji R, Li Y, He C, Zhu X, He A, Lu Y. Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation. Gland Surg. 2020;9:2175-2186 pubmed publisher
Ludwik K, Sandusky Z, Stauffer K, Li Y, Boyd K, O Doherty G, et al. RSK2 Maintains Adult Estrogen Homeostasis by Inhibiting ERK1/2-Mediated Degradation of Estrogen Receptor Alpha. Cell Rep. 2020;32:107931 pubmed publisher
Varga K, Hollósi A, Pászty K, Hegedüs L, Szakacs G, Timar J, et al. Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells. BMC Cancer. 2018;18:1029 pubmed publisher
Dischinger P, Tovar E, Essenburg C, Madaj Z, Gardner E, Callaghan M, et al. NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. NPJ Breast Cancer. 2018;4:29 pubmed publisher
Chen H, Wang J, Zhuang Y, Wu H. Identification of the potential molecular mechanism and driving mutations in the pathogenesis of familial intestinal gastric cancer by whole exome sequencing. Oncol Rep. 2018;40:2316-2324 pubmed publisher
Morgan M, Livingston M, Warrick J, Stanek E, Alarid E, Beebe D, et al. Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model. Sci Rep. 2018;8:7139 pubmed publisher
Zhang J, Qian X, Liu F, Guo X, Gu F, Fu L. Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen. Cancer Biol Med. 2018;15:29-38 pubmed publisher
Marques C, Soares M, Santos A, Correia J, Ferreira F. Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes. Oncotarget. 2017;8:105775-105789 pubmed publisher
Kala R, Tollefsbol T. A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells. PLoS ONE. 2016;11:e0155057 pubmed publisher
Flötotto T, Niederacher D, Hohmann D, Heimerzheim T, Dall P, Djahansouzi S, et al. Molecular mechanism of estrogen receptor (ER)alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoform. J Steroid Biochem Mol Biol. 2004;88:131-42 pubmed
Guler G, Uner A, Guler N, Han S, Iliopoulos D, Hauck W, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer. 2004;100:1605-14 pubmed
Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards R, Boobis A, et al. Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett. 2003;202:17-23 pubmed
Beliakoff J, Bagatell R, Paine Murrieta G, Taylor C, Lykkesfeldt A, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res. 2003;9:4961-71 pubmed
Zinser G, McEleney K, Welsh J. Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice. Mol Cell Endocrinol. 2003;200:67-80 pubmed
Querzoli P, Albonico G, di Iasio M, Ferretti S, Rinaldi R, Cariello A, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat. 2001;66:135-42 pubmed
Suzuki T, Darnel A, Akahira J, Ariga N, Ogawa S, Kaneko C, et al. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab. 2001;86:2250-7 pubmed
Zunarelli E, Nicoll J, Migaldi M, Trentini G. Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome. Breast Cancer Res Treat. 2000;63:193-8 pubmed
El Khissiin A, Journe F, Laios I, Seo H, Leclercq G. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. Steroids. 2000;65:903-13 pubmed
product information
Product Type :
Antibody
Product Name :
Estrogen Receptor alpha Monoclonal Antibody (6F11)
Catalog # :
MA5-13304
Quantity :
500 µL
Price :
US 496
Clonality :
Monoclonal
Host :
Mouse
Reactivity :
Human, Rat
Applications :
Immunocytochemistry: 1:50-1:200, Immunofluorescence: 1:50-1:200, Immunohistochemistry (Frozen): 1:40-1:80, Immunohistochemistry (Paraffin): 1:40-1:80, Immunoprecipitation: 10 µL/mg lysate, Western Blot: 1:50-1:100
Species :
Human, Rat
Clone :
6F11
Isotype :
IgG1
Storage :
4° C
Description :
Estrogen Receptors (ER) are members of the steroid/thyroid hormone receptor superfamily of nuclear receptors. The estrogen receptor is a ligand-activated transcription factor, that when bound to estrogen hormone, induces a conformational change that allows dimerization and binding to estrogen response elements (ERE) in DNA. When bound to EREs, ER can positively or negatively regulate gene transcription through the recruitment of coactivator or corepressor proteins. There are two different forms of the estrogen receptor, alpha and beta, encoded by separate genes (ESR1 and ESR2, respectively). Due to alternative RNA splicing, at least 4 estrogen receptor-alpha isoforms are known to exist (Isoform 1 (66 kDa), Isoform 2 (53 kDa), Isoform 3 (47 kDa), Isoform 4 (35 kDa)). Estrogen receptors are widely expressed in different tissue types and are essential for sexual development and reproductive function. They also play a role in other tissues such as bone. Estrogen receptors are involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis.
Immunogen :
Recombinant estrogen receptor protein (alpha form)
Format :
Liquid
Applications w/Dilutions :
Immunocytochemistry: 1:50-1:200, Immunofluorescence: 1:50-1:200, Immunohistochemistry (Frozen): 1:40-1:80, Immunohistochemistry (Paraffin): 1:40-1:80, Immunoprecipitation: 10 µL/mg lysate, Western Blot: 1:50-1:100
Aliases :
DKFZp686N23123; ER; Er alpha; ER36; ERa; ERALPHA; ER-alpha; ESR; esr 1; Esr1; esr-1; ESRA; Estr; Estra; estradiol receptor; estrogen nuclear receptor alpha; estrogen receptor; estrogen receptor 1; estrogen receptor 1 (alpha); estrogen receptor alpha; estrogen receptor alpha c-terminus splice variant 1-2; estrogen receptor alpha E1-E2-1-2; estrogen receptor alpha E1-N2-E2-1-2; estrogen receptor alpha splice variant, CTERP-1; estrogen receptor alpha splice variant, ERalphaDup5; estrogen receptor alpha splice variant, ERalphai45a; estrogen receptor alpha splice variant, ERalphai45bL; estrogen receptor alpha splice variant, ERalphai45bS; estrogen receptor alpha splice variant, ERalphai45c; estrogen receptor alpha splice variant, ERalphai56; estrogen receptor alpha splice variant, ERalphai67; estrogen receptor alpha variant delta 4; estrogen receptor alpha-like; estrogen receptor protein; estrogen receptor, alpha; ESTRR; hER-alpha36; I79_001166; LOC100351261; Nr3a1; nuclear receptor; Nuclear receptor subfamily 3 group A member 1; RNESTROR; RP1-130E4.1
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA